share_log

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

福泰製藥 | 144:擬議出售證券
美股sec公告 ·  05/28 23:31
牛牛AI助理已提取核心訊息
Vertex Pharmaceuticals Inc. officer Charles F. Wagner Jr. is set to sell 3,250 shares of common stock on 05/28/2024, as announced by the company. The shares, valued at approximately $1,478,067.50, were acquired through restricted stock vesting as part of compensation on two separate occasions, with 1,199 shares obtained on 02/10/2023 and an additional 2,051 shares on 02/13/2023. The planned sale follows the adoption of a trading plan on 02/26/2024. There have been no other reported sales of securities by Wagner in the past three months.
Vertex Pharmaceuticals Inc. officer Charles F. Wagner Jr. is set to sell 3,250 shares of common stock on 05/28/2024, as announced by the company. The shares, valued at approximately $1,478,067.50, were acquired through restricted stock vesting as part of compensation on two separate occasions, with 1,199 shares obtained on 02/10/2023 and an additional 2,051 shares on 02/13/2023. The planned sale follows the adoption of a trading plan on 02/26/2024. There have been no other reported sales of securities by Wagner in the past three months.
據Vertex Pharmicals Inc.宣佈,該公司高管小查爾斯·瓦格納定於2024年5月28日出售3,250股普通股。這些股票價值約1,478,067.50美元,是通過限制性股票歸屬作爲補償的一部分收購的,其中1,199股於2023年10月2日獲得,2023年2月13日又獲得了2,051股。計劃出售是在2024年2月26日通過交易計劃之後進行的。在過去的三個月中,瓦格納沒有其他證券銷售的報道。
據Vertex Pharmicals Inc.宣佈,該公司高管小查爾斯·瓦格納定於2024年5月28日出售3,250股普通股。這些股票價值約1,478,067.50美元,是通過限制性股票歸屬作爲補償的一部分收購的,其中1,199股於2023年10月2日獲得,2023年2月13日又獲得了2,051股。計劃出售是在2024年2月26日通過交易計劃之後進行的。在過去的三個月中,瓦格納沒有其他證券銷售的報道。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。